[ORGANIZATION]
Rhapsido
Featured in 1 tracked story · first seen
Situations
Novartis remibrutinib clinical development
2 clusters · 11 sources · last updated
Latest: Novartis remibrutinib reduces multiple sclerosis relapse rates
Novartis is advancing the clinical application of remibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, across different medical indications. In October 2026, the US Food and Drug Administration (FDA) approved r